The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jo, E.-K.
Right arrow Articles by Miyawaki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jo, E.-K.
Right arrow Articles by Miyawaki, T.
Right arrowPubmed/NCBI databases
*OMIM
*Substance via MeSH
The Journal of Immunology, 2001, 167: 4038-4045.
Copyright © 2001 by The American Association of Immunologists

Characterization of Mutations, Including a Novel Regulatory Defect in the First Intron, in Bruton’s Tyrosine Kinase Gene from Seven Korean X-Linked Agammaglobulinemia Families1

Eun-Kyeong Jo2,*, Hirokazu Kanegane, Shigeaki Nonoyama||, Satoshi Tsukada#, Jae-Ho Lee{dagger}, Kyu Lim{ddagger}, Minho Shong§, Chang-Hwa Song*, Hwa-Jung Kim*, Jeong-Kyu Park* and Toshio Miyawaki

Departments of * Microbiology, {dagger} Pediatrics, {ddagger} Biochemistry, and § Internal Medicine, College of Medicine, Chungnam National University, Taejon, Korea; Department of Pediatrics, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan; || Department of Pediatrics, School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan; and # Department of Molecular Medicine, Osaka University Medical School, Osaka, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In this report, we describe seven mutations, including a novel single base pair substitution in intron 1, of the Bruton’s tyrosine kinase (Btk) gene found in 12 Korean patients with X-linked agammaglobulinemia. Various mutations, including three novel genetic alterations, were discovered using single-strand conformation polymorphism analysis and direct DNA sequencing. The effect of the intron 1 point mutation (intron 1 +5G->A) was further evaluated using reporter constructs. Using luciferase assay experiments, we showed that the transcriptional activity of the mutant was significantly lower than in normal counterparts, indicating that the intronic mutation was functional. In addition, DNase I footprinting analysis showed that a single protected region spanning the position +3 to +15 bp hybridized with a mutant-specific probe, but not with a wild-type probe. EMSA indicated that a distinct nuclear protein has the ability to bind the mutant oligonucleotides to produce a new DNA-protein complex. We also observed decreased expression of Btk proteins in monocytes of patients having the point mutation in intron 1. Taken together with the functional analysis, our results strongly suggest the existence of a novel cis-acting element, which might be involved in the down-regulation of Btk gene transcription. Precise definition of the regulatory defect in the Btk intron 1 may provide valuable clues toward elucidating the pathogenesis of X-linked agammaglobulinemia.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
X-linked agammaglobulinemia (XLA)3 is a disease resulting from mutational defects in the Bruton’s tyrosine kinase (Btk) gene (1). It is characterized by the early onset of bacterial infection, profound hypogammaglobulinemia, a marked decrease in the number of B lymphocytes, and an almost total plasma cell deficiency (2, 3). Although most affected males are recognized as having immunodeficiency early in life, diagnosis may be delayed, particularly in atypical or sporadic cases (4, 5, 6). Since associated infections, particularly bacterial meningitis and pneumonia, are often life-threatening (7), accurate diagnosis and genetic counseling are critical for the management of XLA. Recently, the measurement of intracellular Btk protein expression levels in monocytes has been proposed as a diagnostic tool to evaluate human XLA patients and carriers (8).

Btk is a signal-transducing protein expressed in all hemopoietic lineages, except T cells and NK cells (7, 9, 10, 11). Btk protein is a member of the Tec family of protein tyrosine kinases (Tec kinases), which includes Itk, Tec, Bmx, and Txk. Btk is composed of five distinct structural domains: the pleckstrin homology (PH), Tec homology (TH), Src homology (SH) 3, SH2, and catalytic kinase (SH1) domains (12, 13, 14, 15, 16). In vivo and in vitro studies indicate that Btk protein is essential for B cell survival, cell cycle progression, and proliferation in response to B cell Ag receptor stimulation (17).

The human Btk gene is located in the Xq22 region of the X chromosome, encompassing 37.5 kb and containing 19 exons, 18 of which encode the protein. The first exon and 30 bp of the second exon constitute the 5' untranslated region of the Btk mRNA (18), and a cluster of transcriptional start sites have been identified upstream of exon 1. DNA-based mutation scanning techniques, such as single-strand conformation polymorphism (SSCP), have been used to identify Btk mutations. A database of Btk mutations lists 600 mutation entries from 518 unrelated families, comprising 378 unique molecular events (http://protein.uta.fi/BTKbase/tables.html). Mutations have been identified throughout all five domains of Btk and are associated with reductions in Btk mRNA, protein, and kinase activity (2, 6, 9, 19, 20, 21).

Nevertheless, certain cases have been reported in which reduced Btk mRNA levels were not correlated with mutations in any of the Btk coding regions (20). It is possible that these patients have some transcriptional regulation defect; however, the precise mechanisms of Btk gene regulation in XLA patients that lack Btk mRNA remain to be elucidated. A previous study (22) identified a single base pair substitution (intron 1 +6T->G) in the first intron of Btk in an XLA patient, resulting in decreases in both Btk mRNA expression and luciferase production. Two transcriptional control elements in intron 1 and a strong positive regulator, active in both pre-B cells and B cells, were identified within the first 43 bp of the intron (22).

This report is the first study of Btk deficiency in Korea. We clinically and genetically characterized 12 patients with XLA, identifying seven mutations including three novel genetic alterations (a point mutation in intron 1 and two deletions) of the Btk gene in seven unrelated families. In addition, we used flow cytometric assays to demonstrate deficient Btk expression in patients and cellular mosaicism in carriers. We further analyzed the functional activities of the point mutation in intron 1 and concluded that this mutation is probably involved in the defective regulation of Btk through a pathway dissimilar to that reported previously (22).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Subjects

Seven different Korean XLA families (12 patients) were included in the study (Table IGo). All of the XLA patients were males, ranging in age from 1 to 23 years. Diagnosis was based on 1) an absence of, or severe deficiency in, circulating B cells; 2) a very low level of serum Igs, in particular IgG; and 3) a history of recurrent bacterial infections. The male siblings of 11 of the 12 patients had familial disease histories. Informed consent was obtained from all patients and their family members before inclusion in this study.


View this table:
[in this window]
[in a new window]
  		Table I. Patient laboratory data and family history

 
Infections requiring hospitalization developed in eight patients at a mean age of 9.3 mo (range, 3–28 mo), requiring i.v. Ig replacement therapy. Recurrent ear, nose, and throat infections and pneumonia developed in all eight patients, and Pneumocystis carinii pneumonia was documented in one patient (P7). Chronic sinusitis and otitis medium were documented in two children (P3-1 and P6), and chronic arthritis and epididymitis were diagnosed in patient P4-1. Patient P5 died from liver cirrhosis as a result of chronic viral hepatitis, despite receiving regular i.v. Ig therapy. Currently, the six surviving patients (P2-2 also died) receive regular i.v. Ig infusions. Two apparently healthy children (P3-2, P4-2) were diagnosed as XLA sufferers based solely on their family history, in the absence of any clinical symptoms.

Flow cytometric analysis of cellular Btk expression

Heparinized venous blood samples from patients and family members were fractionated on a Ficoll-Hypaque gradient to isolate PBMC. PBMC were washed three times in PBS (pH 7.4) and analyzed by flow cytometry for Btk expression. Intracellular Btk staining with the anti-Btk mAb (48-2H) was performed as described previously (8). Briefly, PBMC were first stained with PE-labeled anti-CD14 (IgG2a; DAKO, Kyoto, Japan) mAb for 20 min on ice to discriminate monocytes from other cells. The cells were fixed (4% paraformaldehyde in PBS for 15 min at room temperature) and permeabilized (0.1% Triton X-100 in TBS (pH 7.4) with 1 mg/ml BSA for 5 min). These cells were reacted with 2 µg/ml anti-Btk (48-2H) or control IgG1 (DAKO) mAb for 20 min on ice, washed, and further incubated with a 1/2000 dilution of FITC-conjugated goat anti-mouse IgG1 Ab (Southern Biotechnology Associates, Birmingham, AL) for 20 min on ice. The stained cells were analyzed by two-color flow cytometry (EPICS XL-MCL; Corixa, Hialeah, FL).

RT-PCR and DNA sequencing

Total RNA was prepared from PBMC using TRIzol reagent (Life Technologies, Grand Island, NY) according to the manufacturer’s instructions. cDNA was synthesized from RNA using the reverse transcription reaction described previously (20). PCR amplification of the Btk cDNA was performed using seven overlapping PCR primers as described elsewhere (20). The resulting PCR products were purified using a PCR DNA purification system (Promega, Madison, WI). Direct sequencing of the amplified RT-PCR products by the dideoxy nucleotide-chain termination method (23) was performed using the Sequenase 2.0 kit (USB, Cleveland, OH) and the BigDye terminator cycle sequencing kit (PE Applied Biosystems, Foster City, CA) along with an automated Applied Biosystems PRISM 310 genetic analyzer (PE Applied Biosystems). Forward and reverse primers for use in manual DNA sequencing were labeled with {alpha}-35S-dATP, and the reaction products were electrophoresed on denaturing 6% polyacrylamide gels. Mutated sequences were confirmed by opposite-strand sequencing or by sequencing genomic DNA fragments covering intron-exon boundaries.

SSCP and RFLP analyses

For SSCP analysis, 3 µl of PCR product was mixed with 9 µl of sample loading buffer containing 95% formamide, 10 mM NaOH, 0.25% bromphenol blue, and 0.25% xylene cyanol. The samples were denatured for 5 min at 100°C in 1x sample buffer (33 mM Tris-sulfate and 7% glycerol, pH 8.3). The DNA was then resolved by 12% PAGE and stained using a Silver Stain Plus kit (Bio-Rad, Hercules, CA).

In family 1, the G to A substitution predicted the creation of a new MboI restriction endonuclease site. We performed PCR-RFLP in this family and 50 Korean normal controls. The exon 1/intron 1 border covering the -67- to +297-bp region was amplified and purified as described for DNA sequencing, treated with MboI, and analyzed by 2% agarose gel electrophoresis.

Gene reporter constructs

The following reporter constructs were kindly provided by Dr. J. Rohrer and Dr. M. E. Conley (St. Jude Children’s Research Hospital, Memphis, TN): 1) pBtkpro+1029, containing the luciferase reporter gene and pGL2 carrying 1029 bp of intron 1 and the acceptor sequence; 2) pBtkpro+43, having a deletion of pBtkpro; 3) pBtkpro+1029-mt6 containing the intron1 +6T->G mutation; and 4) pBtkpro+43-mt6, a deletion derivative. The construction of the reporter constructs has been described previously (22)

A PCR-based strategy (22) was used to introduce patient DNA mutations into pBtkpro+1029 (pBtkpro+1029-mt5). Briefly, genomic DNA of patient (P1-1) was amplified with the sense primer 5'-CAGACTGTCCTTCCTCTC-3' and the antisense primer 5'-AGCCAGCTCTGACCCTGG-3' and cloned into pBtkpro+1029 at the Ppu10I and KpnI restriction sites. Similarly, a deletion construct (pBtkpro+43-mt5) was made, this time using the RsaI restriction sites. All constructs were checked for correct ligation and for potential PCR-induced sequence errors. Plasmid DNA for transient transfections was prepared by CsCl/EtBr density gradient centrifugation as described by Maniatis et al. (24).

Cell culture

The human pre-B cell line Reh and Burkitt’s lymphoma cell lines Daudi and Raji were maintained as suspension cultures in RPMI 1640 supplemented with 15% heat-inactivated FCS, 2.5 x 10-5 M 2-ME, and 250 ng/ml gentamicin.

Transient transfections

B cells grown in 90-mm culture plates were electroporated with reporter constructs using the Bio-Rad Gene Pulsar (Bio-Rad) as previously described (22). In the case of transient transfection, cells were resuspended in medium containing 20 µg of the test plasmid and 2 µg of the pRL-CMV plasmid (Promega) as a transfection efficiency control. Electroporation was conducted at predetermined voltages (270 V for Reh and Raji and 260 V for Daudi cells), with the capacitance extender set at 960 µF. Thirty-six hours after electroporation, the cells were washed three times in PBS, lysed in 100 µl of reporter lysis buffer, and microcentrifuged for 5 min. The reporter gene activities of 20-µl aliquots of culture supernatants were determined using a luciferase assay system (Promega) and a Lumat LB9507 luminometer (Berthold, Nashu, NH). Luciferase units were normalized using the internal control for transfection efficiency, and all results were expressed as fold increases or decreases over the level produced by cell transfection with the pGL2-basic vector. All experiments were repeated at least three times using two different preparations of each construct tested.

DNase I footprinting assay

The DNA binding sites of nuclear protein factors were determined using a DNase I footprinting assay (25). Nuclear extracts for the DNase I footprinting assay were prepared according to the method of Lim and Chae (25). DNA fragments of ~500 bp, beginning 74 bp upstream of the first exon of Btk and ending 324 bp downstream of the exon, were subcloned from pBtkpro+1029 and mutant constructs (pBtkpro+1029-mt5, pBtkpro+1029-mt6) into the T-easy vector (Promega) along with BamHI and HindIII linkers. Excised BamHI-HindIII DNA fragments from these constructs were top-strand labeled at the BamHI site with [{gamma}-32P]ATP in the presence of T4 polynucleotide kinase and used as either wild-type or mutant probes in the DNase I footprinting assays. End-labeled DNA and nuclear extracts were coincubated for 15 min and treated with freshly diluted DNase I (Takara Shuzo, Otsu, Japan) for 10 min on ice. After extractions with a phenol/chloroform solution and chloroform, the DNA was electrophoresed on a 5% polyacrylamide gel containing 8 M urea and visualized by autoradiography. The relative binding avidities of various DNA probes were determined by comparisons of the band intensities in the presence of a series of dilutions of competing constructs.

Nuclear extracts and EMSA

Nuclear extracts for Raji were prepared according to Park et al. (26). Two double-stranded oligonucleotide probes that covered the -10- to +19-bp region at the exon 1/intron 1 border were made. Probe sequences were as follows: -10+19, 5'-TCA GGA CTG AGG TGG GTC TGG GGT ATG GCA-3'. An additional -10+19 probe including the patient’s G to A mutation at position +5 was also made (-10+19 M). Gel-purified oligonucleotides were labeled with [{gamma}-32P]ATP using T4 polynucleotide kinase and purified on an 8% native polyacrylamide gel. EMSA was performed as previously described (26). Binding reactions in high salt with detergent were conducted in a solution of 1.5 fmol of 32P-labeled DNA, 2 µg of nuclear extract, and 0.5 µg of poly(dI-dC) in 10 mM Tris-HCl (pH 7.9), 5 mM MgCl2, 50 mM KCl, 1 mM DTT, 1 mM EDTA, 0.1% Triton X-100, and 12.5% glycerol. Where indicated, unlabeled double-stranded oligonucleotides were also added as competitor to the binding reaction and incubated for 20 min before the addition of labeled DNA. After incubation, reaction mixtures were analyzed by electrophoresis on 4 or 4.5% native polyacrylamide gels at 160 V in 0.5x Tris-borate-EDTA buffer. Gels were dried and autoradiographed.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Identification of Btk mutations

Patient cDNAs were successfully amplified and the PCR products were directly sequenced. A point mutation in intron 1, a missense mutation, three deletions, and two splicing errors were found. The Btk mutations and their expression in XLA patients are summarized in Table IIGo.


View this table:
[in this window]
[in a new window]
  		Table II. Btk mutations and expression status in XLA patients and carriers as evaluated by a flow cytometric assay

 
The pedigree of family 1 is shown in Fig. 1GoA. A point mutation was observed in the intron 1 region (Fig. 1GoB). The entire coding region and the 5' and 3' untranslated regions of the cDNA were directly sequenced; however, no abnormalities were identified. To determine whether any cryptic splice sites were activated because of the +5 alteration, PCR primers were designed to amplify the cDNA region surrounding the exon 1/exon 2 cDNA border, as previously described (22). When cDNA from freshly isolated PBMC was used as the template, both PCRs showed the expected products. No PCR products using cryptic splice sites were identified (data not shown). Both patient P1-1 and his younger brother (P1-2) showed the same mutation at position 5 in intron 1. Their mother was heterozygous for G/A at this site, implying that she was a carrier. Since the G to A substitution predicted the creation of a new MboI restriction endonuclease site, the sequencing result was further confirmed by RFLP analysis of this family (Fig. 1GoC). As expected, the normal control and DNA of another XLA patient (P3-1) were resistant to MboI. The DNA of each brother was cleaved into identical smaller fragments indicating G to A substitution. Their mother and sister possessed the resistant band seen in the controls as well as two smaller bands identical to the ones in lanes 1 and 2, implying heterozygosity. The characterization of this mutation is further described in the next section.



View larger version (56K):
[in this window]
[in a new window]
  		FIGURE 1. Pedigrees and intron 1 point mutations in family 1. A, Pedigree: male ({square}, {blacksquare}) and female ({odot}) family members are shown. The filled symbols indicate patients with XLA. Dotted circles indicate that the individual is a carrier. Subject numbers are written below their respective symbols. B, The DNA sequences of the intron 1 5' region of control, carrier (mother), P1-1, and P1-2 are shown. The 5' and 3' ends of exon 1 are indicated in the control sequence. *, a G to A transversion. C, RFLP analysis of the Btk exon 1/intron 1 border covering the -67- to +297-bp region. DNA was amplified and analyzed as described in the text. Lane 1, P1-1; lane 2, P1-2; lane 3, mother; lane 4, sister; lane 5, father; and lane 6, P3-1. *, A carrier; extreme left lane, standard size markers, as indicated on the side.

 
Two novel deletion mutations were detected in families 5 and 7. Fig. 2GoA illustrates the pedigree of family 5. SSCP and DNA sequencing analyses of patient P5 showed a 4-bp deletion in exon 8 (Fig. 2Go), which results in a frameshift producing a premature stop codon (K237delX275). In family 5, two maternal aunts did not display any apparent conformational polymorphism in PCR-SSCP, whereas the mother and a third maternal aunt showed heterozygosity at positions 842–845, implying that both were carriers. However, the mutation was absent in the maternal grandmother (Fig. 2GoB). Another novel deletion was found in family 7. PCR amplification of genomic DNA from a patient in this family, using a 5' primer of exon 9 and a 3' primer of exon 11, revealed a PCR product of ~700 bp. This PCR product was correlated with a 980-bp deletion from intron 9+191T to intron 10-215C, which included exon 10. This patient was the only sporadic case in this study, since his mother and brother had normal Btk production by flow cytometry and no mobility shift in PCR-SSCP (data not shown). A deleted guanine at nucleotide position 292, resulting in a frameshift and premature termination (G54delX56), was noted in patient P6.



View larger version (65K):
[in this window]
[in a new window]
  		FIGURE 2. Pedigrees and novel deletion mutations in exon 8 in family 5. A, Pedigree: Male ({square}, {blacksquare}) and female ({circ}, {odot}) family members are shown. The filled symbols indicate patients with XLA. Dotted circles indicate that the individual is a carrier. Subject numbers are written below their respective symbols. B, SSCP analysis of the Btk exon 8: DNA was amplified and analyzed as described in the text. Lane 1, P5; lane 2, mother; lane 3, aunt 1; lane 4, aunt 2; lane 5, aunt 3; lane 6, father; lane 7, grandmother; lane 8, maternal grandmother; and lane 9, normal control. *, A carrier. C, Exon 8 DNA sequence from a normal control, carriers (mother and aunt), a maternal grandmother, and P5. *, A 4-bp deletion.

 
Two splicing errors were found in the genetic material of families 2 and 4. Point mutations in introns 18 (+1G->T) and 6 (+1G->C) resulted in alternative splicing, involving 33 bp in the 3'-terminal of exon 18 in family 2 and skipping exon 6 in family 4 (Table IIGo). The only missense mutation found was in family 3; three patients (P3-1, P3-2, and P3-3) with significant clinical heterogeneity had the same genetic alteration (314T->C) at exon 3, resulting in an amino acid change at codon 61 (I61T).

Functional analysis of intron 1 mutants

Reporter gene analysis. To evaluate the effects of a G to A transversion at position +5 in intron 1 of Btk, the mutant constructs (pBtkpro+1029-mt5 and pBtkpro+43-mt5) were made (Fig. 3GoA). The transcriptional activity of several constructs was measured in luciferase assay experiments (Fig. 3GoB). A 20- to 50-fold increase in transcriptional activity was observed in Raji and Daudi cells transfected with pBtkpro+1029, the construct containing intron 1, when compared with the corresponding pGL2-basic transfectants. The transfected pre-B cell line, Reh, displayed an almost 3-fold increase in reporter gene expression. The transcriptional activity of the construct containing the mutation at position 5 (pBtkpro+1029-mt5) was dramatically reduced (ranging from 0.01- to 0.004-fold lower) in transiently transfected Raji and Daudi B cell lines, compared with the wild-type construct (pBtkpro+1029). A similar, but less dramatic, decrease (0.07-fold) was seen in pBtkpro+1029-mt5 transfected Reh. However, pBtkpro+1029-mt6 showed ~7- to 48-fold more transcriptional activity than pBtkpro+1029-mt5 in B cell lines. All of the pBtkpro+1029-mt5 luciferase levels were above background, and the pBtkpro+1029 and pBtkpro+1029-mt6 luciferase values obtained broadly agreed with those seen in previous studies (22).



View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 3. Relative luciferase activities and DNase I footprinting analysis in intron 1 of the Btk gene. A, A schematic diagram of the reporter constructs containing the 5' portion of Btk intron 1, as defined by Rohrer et al. (22 ). The mutant constructs show the relative locations of previously identified mutation sites (position +6) and those identified in family 1 (position +5). Also shown is the intron 1 acceptor sequence 5' to the start of the luciferase gene (Luc). B, Relative luciferase activities of the normal constructs (wild type) compared with the mutant constructs (Mut6 and Mut5). The increases are relative to pGL2-basic vector. Construct numbers (43, pBtkpro+43; 1029, pBtkpro+1029) are given below the respective bars. Cell lines are indicated in the top left-hand corner of each series. C, DNase I footprinting of the 5' end of the first intron of the Btk gene. A 500-bp BamHI/HindIII DNA fragment spanning the 5' region of intron 1 of the Btk gene and 5' end-labeled on the top strand was incubated with increasing amounts (50, 75, and 100 µg) of nuclear protein prepared from Raji cells and further digested with DNase I, as detailed in the text. Digested DNA was separated by gel electrophoresis and analyzed via autoradiography. The DNA region protected from DNase I digestion is indicated. G, Maxam and Gilbert "G" sequencing ladder; C, control lane containing the labeled probe digested with DNase I, but without added proteins. D, EMSA of the sequence at the exon 1/intron 1 border. Left, A double-stranded oligonucleotide containing the DNA sequence-spanning nts -10 to +19 at the exon/intron border (probe -10+19) and its mutant form (probe -10+19M) were 5' end-labeled and used as a probe in EMSA. Each end-labeled oligomer was incubated with increasing amounts (5, 10, and 20 µg) of crude nuclear proteins from Raji cells and the formation of DNA-protein complexes was evaluated by EMSA. Right, The -10+19M-labeled probe, indicated above the lanes, was incubated in the absence or presence of 200x excess cold probe, as shown below. Arrow, Observed gel shift; P, free probe.

 
Progressive deletions were made from the 3' end of pBtkpro+1029 to localize potential regulatory elements. A positive regulatory element was identified within the first 43 bp of the intron (22) in the pBtkpro+1029 construct. We analyzed the transcriptional activity of pBtkpro+43 and mutant derivatives in both pre-B and B cells. pBtkpro+43 elicited significant, but smaller, amounts of luciferase in reporter gene assays with Raji and Daudi cells than did pBtkpro+1029. However, pBtkpro+43-mt5 expressed >15.1-fold more transcriptional activity than pBtkpro+1029-mt5 in B cells, whereas pBtkpro+43-mt6 gave far lower (1.5- to 3.2-fold) increases in transcriptional activity than did pBtkpro+1029-mt6. These results suggest that different mechanisms controlling Btk gene transcription operate in the two mutant constructs. In addition, greater increases in transcriptional activity were obtained in pre-B-cells when pBtkpro+43-mt6 (17.5-fold) and pBtkpro+43-mt5 (32.6-fold) were used, corroborating a previous study that suggested the presence of a negative regulator within this sequence (22).

DNase I footprinting. We performed DNase I footprinting experiments using a 500-bp DNA fragment probe containing 324 bp of intron 1 to define cis-acting transcriptional modulation elements present at mutation sites. The addition of up to 100 µg of nuclear proteins from Raji cells yielded no DNase I protection in the Btk intron 1 region when the wild-type probe was used (Fig. 3GoC). However, when a probe containing the mutation at position +5 in intron 1 (mut-5) was used, the addition of as little as 50 µg of nuclear protein revealed a protected region spanning positions +3 to +15 bp, with a strongly hypersensitive site in the vicinity of the protected region of the gene. We found the same hypersensitivity site with the bottom strand (data not shown).

In addition, when the probe containing the mutation at position +6 in intron 1 (mut-6) was used, we detected a protected site spanning the +4- to +15-bp region, which was distinct from that found using the mut-5 probe. These results suggested differences in the nuclear factor-binding properties of the mut-5 and mut-6 sequences. Moreover, no additional differences were detected in binding patterns using footprinting analysis with any of the three probes mentioned above. Identical binding patterns were observed when similar amounts of Reh nuclear proteins were used (data not shown).

EMSA. We used EMSA to determine whether the mutant DNA sequences could bind nuclear extracts, as shown in footprinting analysis. Using a sequence spanning nts -10 to +19 at the exon/intron border (probe -10+19) to identify nuclear DNA-binding factors, a single gel shift was observed (Fig. 3GoD, left). When the mutant probe (-10+19 M) was used as a target for DNA, the single band observed for the normal probe was again seen, along with an additional band (Fig. 3GoD, left, band 2), suggesting that the mutation created an additional binding site in this region. In the competition assays, the additional shift with the lower mobility (band 2) was inhibited by the addition of cold -10+19 M oligonucleotide, not by cold -10+19 probe (Fig. 3GoD, right top). Furthermore, this shift was not inhibited by oligonucleotides containing unrelated binding sites for the well-known transcription factors AP-1, OCT-1, and NF-{kappa}B, even when used at a 1000-fold molar excess, indicating the involvement of a novel transcription factor (Fig. 3GoD, right bottom).

Flow cytometric analysis of family 1 and other XLA families

The detection of monocyte-expressed Btk protein by flow cytometric analysis has been previously demonstrated (8). Using this approach, we examined the Btk expression of 10 males and their relatives and found that 9 had coding region mutations leading to defective (mean, 1.6; range, 0.9–2.7%) Btk protein expression in monocytes (Fig. 4Go). In addition, the flow cytometric analysis of PBMC from P1-1 showed diminished Btk expression (18.5%). The flow cytometric assay showed a mosaic pattern of monocyte Btk expression in 12 of 22 sisters or maternal relatives (~55%) of subjects in this study, indicating that they are obligate XLA carriers. A bimodal pattern of monocyte Btk expression was evident in all carriers.



View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 4. Comparisons of Btk protein expression between family 1 and other XLA families with Btk coding region mutations. Mononuclear cells were stained for Btk as described in the text. Btk expression in monocytes was evaluated by gating on the CD14+ population in flow cytometry. The dashed line indicates the control Ab. Five thousand cells were evaluated in each gated population. Flow cytometric data are presented for family 1 (A) and 5 (B).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
This is the first Korean study describing mutations in the Btk gene in patients with XLA; 7 mutations were found in 12 patients. Six of the seven mutations were localized in the Btk coding region, and one point mutation was present in intron 1. Btk protein analysis using flow cytometry clearly showed cellular mosaicism in monocytes from obligate carriers, findings consistent with those obtained using SSCP.

There are >600 mutation entries in the database of XLA mutations (http://protein.uta.fi/BTKbase/tables.html) scattered throughout the Btk gene. Mutation distribution in the five structural domains is roughly proportional to the domain length (27). Although no insertional mutations were discovered, three deletions were detected in this study. A novel 4-bp deletion (nts 842–845) in family 5 was absent in the maternal grandmother, although both the mother and a maternal aunt were obligate carriers. Due to the absence of samples from the patient’s maternal grandfather or great-grandparents, the source of the mutant X chromosome could not be determined in this family. Past studies suggest de novo mutation in oocytes or gonadal mosaicism in certain X-linked hereditary diseases (28). Parolini et al. (29) reported the first demonstration of a family with XLA and gonadal mosaicism. Further studies, such as haplotype analysis, are needed to clarify the origin of the P5 mutation in either male or female germlines. A large deletion (980 bp) encompassing exon 10 was found in the genomic DNA of the only sporadic case in this study (P7). The large deletions in Btk observed in this study, and four large deletions ranging from 2.8 to 38 kb observed in another study (30), emphasize the utility of large-scale sequencing in elucidating disease-causing mutations.

We observed clinical heterogeneity in all of the siblings of families 1, 2, 3, and 4. The most extreme cases were in family 3 and were characterized by missense mutations in the PH domain. Patient P3-1 presented with episodes of severe primary infections, but his brother (P3-2) was healthy. Serum IgG levels were correlated with the clinical condition of the affected members of family 3 (P3-1, 14.0 mg/dl; P3-2, 463.0 mg/dl; P3-3, 281.0 mg/dl). However, similar phenotypic correlations with serum Igs were not found in other families. Phenotypic variation is increasingly recognized in XLA and in other primary immunodeficiencies (27, 31, 32, 33). Other factors may compensate for Btk function in less severely affected individuals (32).

In family 1, we detected a novel point mutation in intron 1 (+1G->A). The patient’s cDNA was normal by direct sequencing, although he had lower amounts of protein. Although the +5 position in the splice donor site is highly conserved and is found in 84% of splice donor sites, we could not find out any deleted or inserted cDNA sequences by RT-PCR and direct sequencing from the patient’s cDNA. Additionally, MboI-RFLP revealed no cleavage patterns in 50 normal controls, indicating that this is not a polymorphic site (data not shown). Since there was no splicing defect in his cDNA, we studied the functional activity of reporter constructs containing this mutation. Previous studies showed that the positive regulatory element in intron 1, identified in the pBtkpro+1029 construct, was active in both B cells and pre-B cells. This suggested that it was not a "classical" enhancer element, since a 79-bp fragment containing the first 43 bp of intron 1 was active only in its original position and orientation (22). We found that pBtkpro+1029-mt5 transcriptional activity production was significantly lower in B cell lines compared with wild-type constructs or another mutant construct, pBtkpro+1029-mt6. Therefore, we hypothesize that the nucleotide at mutation 5 is involved in a critical enhancer element of the first intron and that a mutation at this site affects Btk promoter activity. In addition, there appear to be differences in the mechanisms of transcriptional regulation between the mutant constructs at positions +5 and +6, based on the differential effects of mutant constructs in B cells.

The DNase I footprinting assay identified a strong hypersensitivity site associated with Btk transcriptional regulation, which hybridized with the probe derived from mutation position 5, but not with a wild-type probe, and spanned the region from +3 to +15 bp. Flow cytometric analysis of PBMC from P1-1 showed diminished Btk expression, suggesting that the point mutation in intron 1 decreased Btk protein expression through down-regulation of transcription, whereas mutations in the Btk coding region led to complete shutdown of Btk protein expression. It is interesting that the DNase I-protected region of intron 1 differs from the corresponding sequences in mut-5 and mut-6. Using EMSA, an additional band with lower mobility (band 2) was observed and this binding complex competed for binding with the cold mutant oligonucleotide (-10+19 M), but not with the cold wild-type oligonucleotide, AP-1, OCT-1, or NF-{kappa}B. Combined, these data strongly suggest that the effect of this mutation on transcriptional regulation in B cells might be the result of binding of a novel transcription factor.

A previous study showed that a T to G alteration at position +6 created a new Sp1 binding site (22). Although most Sp1 sites are found within promoter sequences, these functional sites are reported in intronic sequences (34, 35, 36, 37, 38). Similarly, a functional GC-rich sequence (GC box), essential for the activation of human CD23 by EBV, was identified within intron 1 of type CD23 and was shown to bind a subset of GC-rich proteins that were apparently distinct from Sp1 (39).

A search for sequence-specific transcription factors in the region between +3 to +15 bp of intron 1 and other target elements was conducted using the SITES table of TFD, a database of transcription factors maintained by Dr. D. Ghosh at the National Center for Biotechnology Information (National Library of Medicine, National Institutes of Health, Bethesda, MD) (40). The search revealed no significant similarities with any of the potential sites listed in the data bank. Although further studies are clearly indicated, we speculate that an unknown protein factor might be responsible, via binding to the cis-acting element with a point mutation, for the defective regulation of Btk transcription. Our results suggest that several regulatory elements or mechanisms mediate transcriptional regulation of Btk and underline the importance of the first intron in Btk promoter activity. Future studies should clarify the molecular nature of this unknown protein factor and its role in XLA pathogenesis.


   Acknowledgments
 
We thank the many patients and their families for their cooperation; the medical doctors, Drs. Jeong-Soo Kim, Dong-Soo Kim, Soo-Jong Hong, and Hoon-Kook for provision of the blood samples and the clinical data; and Dullei Min and Youngja Song for technical assistance. We also thank Dr. Jurg Rohrer and Dr. Mary Ellen Conley for provision of reporter constructs and critical reading of this manuscript.


   Footnotes
 
1 This work was supported by the Korean Science and Engineering Foundation provided in the program year 1998 (986-0700-005-2). Back

2 Address correspondence and reprint requests to Dr. Eun-Kyeong Jo, Department of Microbiology, School of Medicine, Chungnam National University, 6 Munhwa-dong, Chung-ku, Taejon 301-131, Korea. E-mail address: hayoungj{at}cnu.ac.kr Back

3 Abbreviations used in this paper: XLA, X-linked agammaglobulinemia; Btk, Bruton’s tyrosine kinase; SSCP, single-strand conformation polymorphism; PH, pleckstrin homology; TH, Tec homology; SH, Src homology; pBtkpro+1029, reporter constructs containing the luciferase reporter gene and pGL2 carrying 1029 bp of intron 1 and the acceptor sequence; pBtkpro+43, having a deletion of pBtkpro; pBtkpro+1029-mt6 containing the intron 1 +6T->G mutation; pBtkpro+43-mt6, a deletion derivative; pBtkpro+1029-mt5 containing the intron 1 +5G->A mutation; pBtkpro+43-mt5, a deletion derivative; mut-5, a footprinting probe containing the mutation at position +5 in intron 1; mut-6, a footprinting probe containing the mutation at position +6 in intron 1. Back

Received for publication December 27, 2000. Accepted for publication July 23, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Johannes, F. J., A. Hausser, P. Storz, L. Truckenmuller, G. Link, T. Kawakami, K. Pfizenmaier. 1999. Bruton’s tyrosine kinase (Btk) associates with protein kinase Cµ. FEBS Lett. 461:68.[Medline]
  2. Conley, M. E., M. E. Fitch-Hilgenberg, J. L. Cleveland, O. Parolini, J. Rohrer. 1994. Screening of genomic DNA to identify mutations in the gene for Bruton’s tyrosine kinase. Hum. Mol. Genet. 3:1751.[Abstract/Free Full Text]
  3. Ochs, H. D., C. I. Smith. 1996. X-linked agammaglobulinemia: a clinical and molecular analysis. Medicine 75:287.[Medline]
  4. Conley, M. E., J. M. Puck. 1988. Carrier detection in typical and atypical X-linked gammaglobulinemia. J. Pediatr. 112:688.[Medline]
  5. Vorechkovsky, I., J.-N. Zhou, D. Vetrie, D. Bentley, J. Björkander, L. Hammarström, C. I. E. Smith. 1993. Molecular diagnosis of X-linked agammaglobulinaemia. Lancet 341:1153.
  6. Kornfeld, S. J., R. N. Haire, S. J. Strong, H. Tang, S-SJ. Sung, S. M. Fu, G. W. Litman. 1996. A novel mutation (Cys145stop) in Bruton’s tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male. Mol. Med. 2:619.[Medline]
  7. Vetrie, D., I. Vorechovsky, P. Sideras, J. Holland, A. Davies, F. Flinter, L. Hammarstrom, C. Kinnon, R. Levinsky, M. Bobrow, et al 1993. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361:226.[Medline]
  8. Futatani, T., T. Miyawaki, S. Tsukada, S. Hashimoto, T. Kunikata, S. Arai, M. Kurimoto, Y. Niida, H. Matsuoka, Y. Sakiyama, et al 1998. Deficient expression of Bruton’s tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood 91:595.[Abstract/Free Full Text]
  9. Tsukada, S., D. C. Saffran, D. J. Rawlings, O. Parolini, R. C. Allen, I. Klisak, R. C. Sparkes, H. Kubagawa, T. Mohandas, S. Quan, et al 1993. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72:279.[Medline]
  10. Yamada, N., Y. Kawakami, H. Kimura, H. Fukamachi, G. Baier, A. Altman, T. Kato, Y. Inagaki, T. Kawakami. 1993. Structure and expression of novel protein-tyrosine kinases, Emb and Emt, in hematopoietic cells. Biochem. Biophys. Res. Commun. 192:231.[Medline]
  11. Smith, C. I., B. Baskin, P. Humire-Greiff, J. N. Zhou, P. G. Olsson, H. S. Maniar, P. Kjellen, J. D. Lambris, B. Christensson, L. Hammarstrom, et al 1994. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J. Immunol. 152:557.[Abstract]
  12. Sideras, P., C. I. E. Smith. 1995. Molecular and cellular aspects of X-linked agammaglobulinemia. Adv. Immunol. 59:135.[Medline]
  13. Ohta, Y., R. N. Haire, R. T. Litman, S. M. Fu, R. P. Nelson, J. Kratz, S. J. Kornfeld, M. de la Morena, R. A. Good, G. W. Litman. 1994. Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. Proc. Natl. Acad. Sci. USA 91:9062.[Abstract/Free Full Text]
  14. Sideras, P., S. Müller, H. Shiels, H. Jin, W. N. Khan, L. Nilsson, E. Parkinson, J. D. Thomas, L. Brandén, I. Larrson, et al 1994. Genomic organization of mouse and human Bruton’s agammaglobulinemia tyrosine kinase (Btk) loci. J. Immunol. 153:5607.[Abstract]
  15. Hagemann, T. L., Y. Chen, F. S. Rosen, S. P. Kwan. 1994. Genomic organization of the Btk gene and exon scanning for mutations in patients with X-linked agammaglobulinemia. Hum. Mol. Genet. 3:1743.[Abstract/Free Full Text]
  16. Rohrer, J., O. Parolini, J. W. Belmont, M. E. Conley. 1994. The genomic structure of human BTK, the defective gene in X-linked agammaglobulinemia. Immunogenetics 40:319.[Medline]
  17. Petro, J. B., S. M. Rahman, D. W. Ballard, W. N. Khan. 2000. Bruton’s tyrosine kinase is required for activation of I{kappa}B kinase and nuclear factor {kappa}B in response to B cell receptor engagement. J. Exp. Med. 191:1745.[Abstract/Free Full Text]
  18. Genevier, H. C., S. Hinshelwood, H. B. Gaspar, K. P. Rigley, D. Brown, S. Saeland, F. Rousset, R. J. Levinsky, R. E. Callard, C. Kinnon, R. C. Lovering. 1994. Expression of Bruton’s tyrosine kinase protein within the B cell lineage. Eur. J. Immunol. 24:3100.[Medline]
  19. Saffran, D. C., O. Parolini, M.E. Fitch-Hilgenberg, D. J. Rawlings, D. E. H. Afar, O. N. Witte, M. E. Conley. 1994. Brief report: a point mutation in the SH2 domain of Bruton’s tyrosine kinase in atypical X-linked agammaglobulinemia. N. Engl. J. Med. 330:1488.[Free Full Text]
  20. Hashimoto, S., S. Tsukada, M. Matsushita, T. Miyawaki, Y. Niida, A. Yachie, S. Kobayashi, T. Iwata, H. Hayakawa, H. Matsuoka, et al 1996. Identification of Bruton’s tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. Blood 88:561.[Abstract/Free Full Text]
  21. Bykowsky, M. J., R. N. Haire, Y. Ohta, H. Tang, S.-S. J. Sung, E. S. Veksler, J. M. Greene, S. Fu, G. W. Litman, K. E. Sullivan. 1996. Discordant phenotype in siblings with X-linked agammaglobulinemia. Am. J. Hum. Genet. 58:477.[Medline]
  22. Rohrer, J., M. E. Conley. 1998. Transcriptional regulatory elements within the first intron of Bruton’s tyrosine kinase. Blood 91:214.[Abstract/Free Full Text]
  23. Sanger, F., S. Nicklen, A. R. Coulson. 1977. Nucleotide sequencing with chain-termination inhibitors. Proc. Natl. Acad. Sci. USA 74:5463.[Abstract/Free Full Text]
  24. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Purification of plasmid DNA. In Molecular Cloning: A Laboratory Manual. J. Sambrook, E.F. Fritsch, and T. Maniatis, eds. Cold Spring Harbor Lab. Press, Cold Spring Harbor, NY, p. 1.42.
  25. Lim, K., C. B. Chae. 1992. Presence of a repressor protein for testis-specific H2B (TH2B) histone gene in early stages of spermatogenesis. J. Biol. Chem. 267:15271.[Abstract/Free Full Text]
  26. Park, E. S., H. Kim, J. M. Suh, S. J. Park, S. H. You, H. K. Chung, K. W. Lee, O. Y. Kwon, B. Y. Cho, Y. K. Kim, et al 2000. Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway. Mol. Endocrinol. 14:662.[Abstract/Free Full Text]
  27. Vihinen, M., O. Brandau, L. J. Branden, S. P. Kwan, I. Lappalainen, T. Lester, J. G. Noordzij, H. D. Ochs, J. Ollila, S. M. Pienaar, et al 1998. BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic Acids Res. 26:242.[Abstract/Free Full Text]
  28. Jeanpierre, M.. 1992. Germinal mosaicism and risk calculation in X-linked diseases. Am. J. Hum. Genet. 50:960.[Medline]
  29. Parolini, O., J. F. Hejtmancik, R. C. Allen, J. W. Belmont, G. L. Lassiter, M. J. Henry, D. F. Barker, M. E. Conley. 1993. Linkage analysis and physical mapping near the gene for X-linked agammaglobulinemia at Xq22. Genomics 15:342.[Medline]
  30. Rohrer, J., Y. Minegishi, D. Richter, J. Eguiguren, M. E. Conley. 1999. Unusual mutations in Btk: an insertion, a duplication, an inversion, and four large deletions. Clin. Immunol. 90:28.[Medline]
  31. Gaspar, H. B., M. Ferrando, I. Caragol, M. Hernandez, J. M. Bertran, X. De Gracia, T. Lester, C. Kinnon, E. Ashton, T. Espanol. 2000. Kinase mutant Btk results in atypical X-linked agammaglobulinaemia phenotype. Clin. Exp. Immunol. 120:346.[Medline]
  32. Kornfeld, S. J., R. N. Haire, S. J. Strong, E. N. Brigino, H. Tang, S. S. Sung, S. M. Fu, G. W. Litman. 1997. Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family. J. Allergy Clin. Immunol. 100:702.[Medline]
  33. Minegishi, Y., J. Rohrer, M. E. Conley. 1999. Recent progress in the diagnosis and treatment of patients with defects in early B-cell development. Curr. Opin. Pediatr. 11:528.[Medline]
  34. Rotheneder, H., M. Grabner, E. Wintersberger. 1991. Presence of regulatory sequences within intron 2 of the mouse thymidine kinase gene. Nucleic Acids Res. 19:6805.[Abstract/Free Full Text]
  35. Pogulis, R. J., S. O. Freytag. 1993. Contribution of specific cis-acting elements to activity of the mouse pro-{alpha}2(I) collagen enhancer. J. Biol. Chem. 268:2493.[Abstract/Free Full Text]
  36. Henkel, G., M. A. Brown. 1994. PU.1 and GATA: components of a mast cell-specific interleukin 4 intronic enhancer. Proc. Natl. Acad. Sci. USA 91:7737.[Abstract/Free Full Text]
  37. Wakabayashi-Ito, N., S. Nagata. 1994. Characterization of the regulatory elements in the promoter of the human elongation factor-1{alpha} gene. J. Biol. Chem. 269:29831.[Abstract/Free Full Text]
  38. Hamann, L., K. U. Bayer, K. Jensen, K. Harbers. 1994. Interaction of several related GC-box- and GT-box-binding proteins with the intronic enhancer is required for differential expression of the gb110 gene in embryonal carcinoma cells. Mol. Cell. Biol. 14:5786.[Abstract/Free Full Text]
  39. Lacy, J., G. Roth, B. Shieh. 1994. Regulation of the human IgE receptor (Fc{epsilon}RII/CD23) by EBV: localization of an intron EBV-responsive enhancer and characterization of its cognate GC-box binding factors. J. Immunol. 153:5537.[Abstract]
  40. Ghosh, D.. 2000. Object-oriented transcription factors database (ooTFD). Nucleic Acids Res. 28:308.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
M. Sironi, G. Menozzi, G. P. Comi, R. Cagliani, N. Bresolin, and U. Pozzoli
Analysis of intronic conserved elements indicates that functional complexity might represent a major source of negative selection on non-coding sequences
Hum. Mol. Genet., September 1, 2005; 14(17): 2533 - 2546.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jo, E.-K.
Right arrow Articles by Miyawaki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jo, E.-K.
Right arrow Articles by Miyawaki, T.
Right arrowPubmed/NCBI databases
*OMIM
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS